Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH
SUZHOU, China and MÖLNDAL, Sweden, July 1, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK), and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL) announce…
News provided by PR Newswire.
